Cite
The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results.
MLA
Portugal, Cecilia, et al. “The Anticoagulation Length of Therapy and Risk of New Adverse Events in Venous Thromboembolism (ALTERNATIVE) Study: Design and Survey Results.” PloS One, vol. 17, no. 12, Dec. 2022, p. e0277961. EBSCOhost, https://doi.org/10.1371/journal.pone.0277961.
APA
Portugal, C., Fang, M. C., Go, A. S., Zhou, H., Chang, J., Prasad, P., Fan, D., Garcia, E. A., Sung, S. H., & Reynolds, K. (2022). The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results. PloS One, 17(12), e0277961. https://doi.org/10.1371/journal.pone.0277961
Chicago
Portugal, Cecilia, Margaret C Fang, Alan S Go, Hui Zhou, John Chang, Priya Prasad, Dongjie Fan, Elisha A Garcia, Sue Hee Sung, and Kristi Reynolds. 2022. “The Anticoagulation Length of Therapy and Risk of New Adverse Events in Venous Thromboembolism (ALTERNATIVE) Study: Design and Survey Results.” PloS One 17 (12): e0277961. doi:10.1371/journal.pone.0277961.